|
|
Article: Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial.
- Article from:
- Business Wire
- Article date:
- June 16, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Approval Paves Way for US and European Trials That Will Enroll Patients Diagnosed with Critical Limb Ischemia Who are Facing Amputation
HAIFA, Israel -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, has approved the Company's Clinical Trial Application (CTA) and granted approval to begin clinical trials with its placental-derived adherent stromal cell product, termed PLX-PAD, for the treatment of ...